Hovione Farmaciência SA

美迪西是一家专业的生物医药临床前综合研发服务 CRO，为全球的医药企业和科研机构提供全方位的符合国内及国际申报标准的一站式新药临床前研发服务。20多年深耕生物医药临床前研发，美迪西已为全球超2000家客户提供药物研发服务，参与研发完成的新药及仿制药项目已有520件IND获批临床。 2020年以来，美迪西基于自身成熟的CMC平台积极拓展CDMO业务，为客户提供原料药和制剂的定制化产品服务。目前。美迪西正依托一流的研发团队，加强全球质量和监管，积极开拓海外市场，全面构筑技术和市场的“护城河”。 近日，上海美迪西生物医药股份有限公司（股票代码：688202.SH）（以下简称“美迪西”）宣布，任命雒家良博士为首席运营官&药学研究部高级副总裁。 雒家良 博士 美迪西首席运营官&药学研究部高级副总裁 雒家良，北京大学化学系学士，中欧国际管理学院管理学博士，拥有超过30年的深厚生物医药行业经验。他不仅在原料药和制剂药物的研发与市场营销领域有第一手的成功运作经验，还在国际GMP规范（cGMP）及EHS管理体系等方面有着独到的见解和丰富的实践经验。 加入美迪西之前，雒博士曾在杜邦中国、辉瑞制药、龙沙中国，iMAX/Hovione等多家国内外知名药企担任高级管理职务，成功领导了多个项目的市场拓展与业绩增长。多元的医药背景和丰富的工作积淀让他拥有卓越的全球视野，深谙国际运营之道，具备洞察新形势的策略远见。 雒家良 博士 美迪西首席运营官&药学研究部高级副总裁 “美迪西作为一站式生物医药临床前研发服务平台，始终站在科技创新的前沿，引领行业发展新方向。非常荣幸能够加入美迪西，我将运用自己在生物医药行业的丰富经验和国际化战略思维，推动美迪西在CDMO领域实现全球范围内的战略拓展，为全球客户提供更加优质、高效的服务，共同创造更多价值。” 陈春麟 博士 美迪西创始人&CEO “欢迎雒博士加入美迪西。他拥有国际前沿的药物研发技术，从业经历横越中国、美国、欧洲、日韩等地区，既深谙本土管理实践，又具备前瞻性的国际化战略视野，将助力全球化运营，并推动CDMO领域的进一步拓展。期待在雒博士的带领下，美迪西能够更快地打开国际市场新局面，赋能全球新药加速研发。” 服务平台推荐 ＞＞ 点击阅读 美迪西核酸药物研发服务平台 ＞＞ 点击阅读 美迪西ADC药物研发服务平台 ＞＞ 点击阅读 美迪西PROTAC药物研发服务平台 ＞＞ 点击阅读 美迪西抗体药物研发服务平台 ＞＞ 点击阅读 美迪西细胞与基因治疗药物研发服务平台 ＞＞ 点击阅读 直播预告 关于美迪西 美迪西（股票代码：688202.SH）成立于2004年，总部位于上海，致力于为全球制药企业、研究机构及科研工作者提供全方位的临床前新药研究服务。美迪西的一站式综合服务以强有力的项目管理和更高效、高性价比的研发服务助力客户加速新药研发进程，服务涵盖医药临床前新药研究的全过程，包括药物发现、药学研究及临床前研究。至2024年底，美迪西已为全球超2000家客户提供药物研发服务，参与研发完成的新药及仿制药项目已有约520件IND获批临床，与国内外优质客户共同成长。美迪西将继续立足全球视野，聚力中国创新，为人类健康贡献力量！

Welcome to Endpoints News ’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. The FDA has accepted Satsuma Pharmaceuticals’ NDA resubmission for its nasal migraine drug, dubbed STS101, with a PDUFA date of April 30, according to a Tuesday release. The agency previously rejected the drug in January over CMC issues. Hovione is expanding its manufacturing facility in Cork, Ireland and East Windsor, NJ, the company said Tuesday. The expansion will add 40 new jobs across both locations and will boost its spray drying services for oral and inhaled drugs. Liquids are fed into hot nitrogen gas and then rapidly dried to become a solid product. No financial details were disclosed. German CDMO Adragos Pharma is acquiring aseptic fill-finish manufacturer Baccinex, the company said Monday. Adragos will gain Baccinex’s factory in Jura, Switzerland. No financial or timeline details were given. Gelteq said Tuesday it will start making 400,000 units of its gel solution, which is used for drug delivery, for clients in the US and Australia. A new draft of US legislation was introduced on Thursday, which has called for more information to be added to the Federal Food, Drug and Cosmetic Act. The bill seeks to increase the monitoring of drugs to prevent shortages. Reagent supplier Gemini Bioproducts has acquired Bio-Techne’s fetal bovine serum portfolio, the company said Monday. Gemini will thus handle the manufacturing and global sales for three fetal bovine serum brands.

Hovione has been recognized as a Top Employer in all four of its manufacturing sites, in Lisbon (Portugal), Cork (Ireland), East Windsor (NJ) and Macau. Hovione is the first company to be certified as a Top Employer in Macau. Hovione's 3 other sites, who had achieved Top Employer status in 2023, showed improved results this year. LISBON, Portugal , Jan. 18, 2024 /PRNewswire/ -- Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, is delighted to announce that it has been recognized as a Top Employer in all four of its manufacturing sites. Hovione is the first ever company to be certified as a Top Employer in Macau. Continue Reading All Four Hovione Sites recognised as Top Employer Hovione's Largest Manufacturing site in Lisbon Hovione is the first company to be certified Top Employer in Macau 'Being a Top Employer is an integral component of Hovione's People Strategy' Ilda Ventura, Vice President for Human resources